Medtronic (MDT) Tops Q1 EPS by 3c, Beats on Revenue; Offers FY26 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
Medtronic, Inc. (mdt) PT Raised to $107 at Evercore ISI
August 19, 2025 4:15 PM EDTEvercore ISI analyst Vijay Kumar raised the price target on Medtronic, Inc. (NYSE: mdt) to $107.00 (from $106.00) while maintaining a Outperform rating.
The analyst comments "Thesis Update: Im in the EU & thought the Caesars phrase (w some tweaks) was apt in... More
TD Cowen Reiterates Buy Rating on Medtronic, Inc. (MDT)
August 19, 2025 8:32 AM EDTTD Cowen analyst Joshua Jennings reiterated a Buy rating and $106.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "MDT reported F1Q'26 adjusted revenue of $8.54B with underlying organic growth of 4.8%. Reported revenue exceeded the $8.38B consensus target,... More
Truist Securities Reiterates Hold Rating on Medtronic, Inc. (MDT)
August 19, 2025 8:30 AM EDTTruist Securities analyst Richard Newitter reiterated a Hold rating and $92.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "MDT's 4.8% organic rev growth was roughly in-line with 4.9% CNS, while higher reported rev (on FX) and (+$0.02 non-op items) drove a slight EPS beat ($1.26 vs CNS $1.23) on roughly... More
Goldman on Medtronic, Inc. (MDT), 'believe investors had expected total organic growth acceleration to follow the strong performance in CAS'
August 19, 2025 8:05 AM EDTGoldman Sachs analyst David Roman reiterated a Sell rating and $78.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "This morning, Medtronic reported 1QFY26 that on a reported basis exceeded both GSe/Consensus (Visible Alpha consensus Data, unless otherwise noted). On an... More
Raymond James on Medtronic, Inc. (MDT) Earnings: 'All in, this result and guide fell short of our elevated expectations'
August 19, 2025 8:04 AM EDTRaymond James analyst Jayson Bedford reiterated a Market Perform rating and {REMOVEPT} price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "F1Q revenue beat consensus (by ~2%), but this was due to FX and Other revenue as organic growth of 4.8% y/y... More
Stifel Reiterates Hold Rating on Medtronic, Inc. (MDT)
August 19, 2025 8:01 AM EDTStifel analyst Rick Wise reiterated a Hold rating and $87.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "Reporting yet another largely as expected quarter, F1Q26 performance was positively just above Consensus for both organic growth and EPS...and this... More
Mizuho on Medtronic, Inc. (MDT): 'Largely Inline Print Likely Overshadowed by New Board Appointees'
August 19, 2025 7:58 AM EDTMizuho analyst Anthony Petrone reiterated an Outperform rating and $100.00 price target on Medtronic, Inc. (NYSE: MDT)
The analyst comments "MDT reported a +$195mn/+$0.03 beat driven by strong performances across Cardiovascular (+$92mn ahead of Street), Diabetes (+22mn ahead of Street) and MedSurg... More
